Wang J - Search Results

1

Letter: distinct hepatitis B virus relapse rates after discontinuing tenofovir and entecavir therapy in chronic hepatitis B patients.

Huang R, Yao R, Wu W, Wang J, Wu C. Huang R, et al. Among authors: wang j. Aliment Pharmacol Ther. 2019 Apr;49(8):1105-1106. doi: 10.1111/apt.15150. Aliment Pharmacol Ther. 2019. PMID: 30920033 No abstract available.

2

Letter: use of collagen proportionate area to quantify liver fibrosis and predict clinical outcomes in non-alcoholic fatty liver disease.

Huang R, Wu W, Wang J, Zhang Z, Wu C. Huang R, et al. Among authors: wang j. Aliment Pharmacol Ther. 2019 Aug;50(3):338. doi: 10.1111/apt.15362. Aliment Pharmacol Ther. 2019. PMID: 31313357 No abstract available.

3

Letter: clinical outcomes after long-term entecavir or tenofovir treatment in patients with hepatitis D and advanced fibrosis.

Huang R, Wang J, Wu W, Yan X, Wu C. Huang R, et al. Among authors: wang j. Aliment Pharmacol Ther. 2019 Aug;50(4):471. doi: 10.1111/apt.15367. Aliment Pharmacol Ther. 2019. PMID: 31359471 No abstract available.

4

Letter: risk of developing hepatocellular carcinoma in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation.

Huang R, Wang J, Yan X, Xia J, Wu C. Huang R, et al. Among authors: wang j. Aliment Pharmacol Ther. 2019 Sep;50(5):618-619. doi: 10.1111/apt.15423. Aliment Pharmacol Ther. 2019. PMID: 31414546 No abstract available.

5

Profiles of serum soluble programmed death-1 and programmed death-ligand 1 levels in chronic hepatitis B virus-infected patients with different disease phases and after anti-viral treatment.

Xia J, Huang R, Chen Y, Liu Y, Wang J, Yan X, Zhang Z, Wu C. Xia J, et al. Among authors: wang j. Aliment Pharmacol Ther. 2020 Jun;51(11):1180-1187. doi: 10.1111/apt.15732. Epub 2020 May 3. Aliment Pharmacol Ther. 2020. PMID: 32363582

6

Letter: programmed death-1-a predictor for antiviral treatment in chronic hepatitis B. Authors' reply.

Huang R, Xia J, Wang J, Chen Y, Wu C. Huang R, et al. Among authors: wang j. Aliment Pharmacol Ther. 2020 Aug;52(4):749-750. doi: 10.1111/apt.15924. Aliment Pharmacol Ther. 2020. PMID: 32886394 No abstract available.

7

Letter: rates and determinants of significant liver inflammation in chronic hepatitis B virus-infected patients with low ALT levels in the absence of significant fibrosis.

Huang R, Liu J, Wang J, Wu C. Huang R, et al. Among authors: wang j. Aliment Pharmacol Ther. 2021 Jan;53(1):213-214. doi: 10.1111/apt.16164. Aliment Pharmacol Ther. 2021. PMID: 33333604 No abstract available.

8

Letter: serum hepatitis B virus DNA and risk of hepatocellular carcinoma in patients with chronic hepatitis B.

Huang R, Liu J, Wang J, Yan X, Wu C. Huang R, et al. Among authors: wang j. Aliment Pharmacol Ther. 2021 Mar;53(6):761-762. doi: 10.1111/apt.16264. Aliment Pharmacol Ther. 2021. PMID: 33599329 No abstract available.

9

Distribution and clinical characteristics of patients with chronic hepatitis B virus infection in the grey zone.

Yao K, Liu J, Wang J, Yan X, Xia J, Yang Y, Wu W, Liu Y, Chen Y, Zhang Z, Li J, Huang R, Wu C. Yao K, et al. Among authors: wang j. J Viral Hepat. 2021 Jul;28(7):1025-1033. doi: 10.1111/jvh.13511. Epub 2021 Apr 26. J Viral Hepat. 2021. PMID: 33797145

10

Letter: tenofovir versus entecavir for hepatocellular carcinoma prevention in chronic hepatitis B-related compensated cirrhosis.

Huang R, Liu J, Wang J, Wu C. Huang R, et al. Among authors: wang j. Aliment Pharmacol Ther. 2021 May;53(9):1040-1041. doi: 10.1111/apt.16273. Aliment Pharmacol Ther. 2021. PMID: 33831236 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

218,539 results

Search Page

Filters